late-stage cholangiocarcinoma cholangiocarcinoma, Atractylodes lancea standardized extract phase IIa clinical trial
Conditions
Interventions
1 capsule formulation consists of 601 mg A. lancea standardized extract of A. lacea,1 capsule formulation consists of 601 mg A. lancea standardized extract of A. lacea,standard supportive care for c
A. lancea at 1,000 mg per day for 90 days together with standard supportive care,A. lancea at 1,000 mg per day for 14 days, followed by 1,500 mg for 14 days, followed by 2,000 mg for 62 days together
Sponsors
National Research Council of Thailand (NRCT)
Eligibility
Inclusion criteria
Inclusion criteria:
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pharmacokinetic parameters Day 0 (at 0, 0.5, 1, 1.5, 2, 2.5, 3,4,5 and 6 hours); day 15 (at 0,0.5,1,1.5,2.5,3,4,5,6 hours); day 29 (at 0,0.5,1,1.5,2,2.5,3,4.5 and 6 hours) pharmacokinetic analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse events weekly for 4 months clinical signs and symptoms and laboratory tests | — |
Countries
Thailand
Contacts
Public ContactKesara NaBangchang
Thammasat University
Outcome results
None listed